Log in

NASDAQ:STSASatsuma Pharmaceuticals Stock Price, Forecast & News

$27.25
+0.05 (+0.18 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$25.85
Now: $27.25
$27.52
50-Day Range
$20.71
MA: $27.50
$34.69
52-Week Range
$8.61
Now: $27.25
$36.10
Volume41,398 shs
Average Volume116,369 shs
Market Capitalization$473.88 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.
Read More
Satsuma Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryRegional Banks
SectorMedical
Current SymbolNASDAQ:STSA
CUSIP85931930
Phone650-410-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.64 per share

Profitability

Miscellaneous

Employees11
Market Cap$473.88 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive STSA News and Ratings via Email

Sign-up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter.

Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions

How has Satsuma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Satsuma Pharmaceuticals' stock was trading at $23.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STSA stock has increased by 14.7% and is now trading at $27.25. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Satsuma Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Satsuma Pharmaceuticals.

When is Satsuma Pharmaceuticals' next earnings date?

Satsuma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Satsuma Pharmaceuticals.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals (NASDAQ:STSA) released its earnings results on Tuesday, May, 12th. The financial services provider reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.01. View Satsuma Pharmaceuticals' earnings history.

What price target have analysts set for STSA?

3 analysts have issued 1-year target prices for Satsuma Pharmaceuticals' stock. Their forecasts range from $32.00 to $35.00. On average, they anticipate Satsuma Pharmaceuticals' stock price to reach $33.00 in the next year. This suggests a possible upside of 21.1% from the stock's current price. View analysts' price targets for Satsuma Pharmaceuticals.

Has Satsuma Pharmaceuticals been receiving favorable news coverage?

Headlines about STSA stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Satsuma Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the financial services provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about Satsuma Pharmaceuticals.

Are investors shorting Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 85,400 shares, an increase of 6.8% from the May 31st total of 80,000 shares. Based on an average daily volume of 42,200 shares, the short-interest ratio is currently 2.0 days. Currently, 0.7% of the company's stock are short sold. View Satsuma Pharmaceuticals' Current Options Chain.

Who are some of Satsuma Pharmaceuticals' key competitors?

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include AbbVie (ABBV), Applied Therapeutics (APLT), Canadian Natural Resources (CNQ), Crispr Therapeutics (CRSP), Enbridge (ENB), Enterprise Products Partners (EPD), Gilead Sciences (GILD), GlaxoSmithKline (GSK), ImmunoGen (IMGN) and Karuna Therapeutics (KRTX).

Who are Satsuma Pharmaceuticals' key executives?

Satsuma Pharmaceuticals' management team includes the following people:
  • Mr. John A. Kollins, Pres, CEO & Director (Age 56)
  • Dr. Detlef F. Albrecht, Chief Medical Officer (Age 58)
  • Mr. Thomas P. O'Neil, Chief Financial Officer (Age 54)
  • Mr. Mic Iwashima, VP & Head of Operations (Age 41)
  • Mr. Robert Schultz, VP & Head of CMC (Age 55)

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $27.25.

How big of a company is Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals has a market capitalization of $473.88 million. The financial services provider earns $-28,170,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Satsuma Pharmaceuticals employs 11 workers across the globe.

What is Satsuma Pharmaceuticals' official website?

The official website for Satsuma Pharmaceuticals is www.satsumarx.com.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 94080. The financial services provider can be reached via phone at 650-410-3200.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.